These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 18922978)

  • 1. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.
    Linderholm BK; Hellborg H; Johansson U; Skoog L; Lehtiö J
    Breast Cancer Res Treat; 2011 Jan; 125(2):457-65. PubMed ID: 21110084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.
    Weldon CB; Parker AP; Patten D; Elliott S; Tang Y; Frigo DE; Dugan CM; Coakley EL; Butler NN; Clayton JL; Alam J; Curiel TJ; Beckman BS; Jaffe BM; Burow ME
    Int J Oncol; 2004 Jun; 24(6):1473-80. PubMed ID: 15138590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.
    Das B; Yeger H; Tsuchida R; Torkin R; Gee MF; Thorner PS; Shibuya M; Malkin D; Baruchel S
    Cancer Res; 2005 Aug; 65(16):7267-75. PubMed ID: 16103078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
    Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?
    Scherbakov AM; Lobanova YS; Shatskaya VA; Onopchenko OV; Gershtein ES; Krasil'nikov MA
    Breast Cancer Res Treat; 2006 Nov; 100(1):1-11. PubMed ID: 16990991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells.
    Kim CG; Choi BH; Son SW; Yi SJ; Shin SY; Lee YH
    Cell Signal; 2007 Jun; 19(6):1290-300. PubMed ID: 17307334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
    Weigand M; Hantel P; Kreienberg R; Waltenberger J
    Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
    Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
    Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of stress activated protein kinases (JNK and p38) in 1,25 dihydroxyvitamin D3-induced breast cell death.
    Brosseau CM; Pirianov G; Colston KW
    Steroids; 2010 Dec; 75(13-14):1082-8. PubMed ID: 20654640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38.
    Lamalice L; Houle F; Jourdan G; Huot J
    Oncogene; 2004 Jan; 23(2):434-45. PubMed ID: 14724572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procollagen I COOH-terminal fragment induces VEGF-A and CXCR4 expression in breast carcinoma cells.
    Palmieri D; Astigiano S; Barbieri O; Ferrari N; Marchisio S; Ulivi V; Volta C; Manduca P
    Exp Cell Res; 2008 Jul; 314(11-12):2289-98. PubMed ID: 18570923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
    Garvin S; Dabrosin C
    Cancer Res; 2003 Dec; 63(24):8742-8. PubMed ID: 14695189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.